Saturday 17 October 2026
Export LYEL’s income statement to Excel — free account
Lyell Immunopharma, Inc.
LYEL Healthcare Biotechnology
Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024. In the quarter to June 2026, revenue fell 50.0%, EPS grew 33.6% and free cash flow grew 1.31%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
8.12
0.07
−0.85%
Follow LYEL
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 5 | 2 | 2 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 36.98 | 36.98 | 98.78 | 9.80 | 4,073.60 | 2,743.40 | 14,614.52 |
Altman Z-Score |
— | — | — | 2.47 | 4.00 | 0.95 | (4.52) | (5.10) |
Altman Z″-Score (non-manufacturers) |
— | — | 1.08 | 5.34 | 8.68 | 5.21 | (5.77) | (13.93) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (8.68) | (8.68) | (31.67) | (20.62) | (13.03) | (3.54) | (16.31) |
P/B ratio |
— | 0.00 | 0.00 | 1.13 | 1.00 | 0.81 | 0.44 | 2.12 |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.13 | 1.00 | 0.81 | 0.44 | 2.12 |
EV/Sales |
— | (39.71) | (39.71) | 41.05 | 2.24 | (128.12) | (3,330.82) | 7,747.29 |
EV/EBITDA |
— | 1.41 | 1.41 | 0.00 | 0.00 | 0.07 | 0.57 | 0.00 |
EV/Operating CF |
— | 1.61 | 1.61 | (3.46) | (1.12) | 0.10 | 1.25 | (1.86) |
EV/FCF |
— | 1.18 | 1.18 | (2.28) | (0.98) | 0.10 | 1.05 | (1.45) |
Quick Ratio |
— | 19.82 | 12.43 | 13.15 | 17.29 | 15.82 | 6.89 | 5.00 |
Current Ratio |
— | 20.00 | 12.53 | 13.40 | 17.59 | 16.07 | 7.06 | 5.28 |
Net Debt/EBITDA |
— | 4.26 | 2.96 | 3.09 | 3.77 | 2.31 | 1.05 | 0.94 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.02 | 0.01 | 0.08 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | (0.30) | 0.77 | 0.50 | 0.93 | 0.70 | 0.47 | 0.55 |
Capex/Depreciation |
— | 61.25 | (10.65) | (4.22) | (1.42) | (0.25) | (6.43) | (6.34) |
| — | 64.61% | 103.12% | (78.53%) | (20.77%) | (31.53%) | (66.10%) | (86.98%) | |
| — | 0.00% | (45.81%) | (24.58%) | (17.74%) | (27.81%) | (55.28%) | (66.06%) | |
ROIC |
— | 0.00% | 0.00% | (42.62%) | (60.54%) | (141.99%) | (1,823.39%) | (17,146.38%) |
Return on Tangible Assets |
— | (28.25%) | (32.24%) | (35.76%) | (24.84%) | (37.67%) | (91.71%) | (111.43%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 9,679.60% | 2,349.70% | 1,302.28% | 187.98% | 140,726.92% | 281,316.39% | 440,763.89% |
Selling, General and Administrative Expense of Revenue |
— | 5,959.06% | 604.45% | 836.22% | 138.52% | 51,525.38% | 85,313.11% | 125,375.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 2,394.52% | 428.84% | 584.05% | 96.74% | 36,218.46% | 54,334.43% | 116,191.67% |
Graham Net Nets |
— | 2.09 | 2.09 | 0.41 | 0.66 | 0.87 | 1.62 | 0.32 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (82.53%) | (82.53%) | (65.08%) | (22.02%) | (44.08%) | (204.69%) | (52.96%) |
Free Cash Flow Yield |
— | (90.89%) | (90.89%) | (18.23%) | (23.35%) | (31.42%) | (116.05%) | (36.44%) |
Revenue per Share |
— | 2.42 | 11.70 | 1.57 | 6.85 | 0.01 | 0.00 | 0.00 |
Operating CF per Share |
— | 145.39 | (242.68) | (18.58) | (13.72) | (13.04) | (12.42) | (8.78) |
Capex per Share |
— | (59.10) | (77.66) | (9.64) | (1.96) | (0.21) | (2.43) | (2.44) |
Free Cash Flow per Share |
— | 86.29 | (320.34) | (28.22) | (15.69) | (13.26) | (14.85) | (11.22) |
Cash per Share |
— | 1,605.89 | 924.15 | 90.47 | 51.82 | 43.53 | 28.34 | 14.46 |
Shareholders Equity per Share |
— | 0.00 | (441.29) | 136.82 | 67.45 | 52.19 | 29.28 | 14.52 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (441.29) | 136.82 | 67.45 | 52.19 | 29.28 | 14.52 |
Free Cash Flow |
— | 23.43 | (212.35) | (191.75) | (193.83) | (166.38) | (194.20) | (191.71) |
Working Capital |
— | 418.00 | 568.26 | 579.55 | 614.27 | 520.17 | 325.81 | 211.53 |
Capital Expenditures |
— | (16.05) | (51.48) | (65.50) | (24.28) | (2.69) | (31.81) | (41.69) |
Net Current Asset Value |
— | 440.00 | (583.26) | 428.67 | 546.99 | 459.61 | 271.56 | 169.09 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.57 | 0.00 |
Capex to Sales |
— | 24.42 | 6.64 | 6.15 | 0.29 | 20.66 | 521.48 | 1,158.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | (0.01) | 0.06 | 0.13 | 0.14 | 0.10 | 0.10 | 0.19 |
Cash ROIC |
— | 5.37% | (66.34%) | (12.41%) | (13.16%) | (13.85%) | (25.78%) | (38.70%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 6.00 | 6.20 | 6.30 | 3.56 | 4.37 | 5.09 | 4.13 |
Average Assets |
— | 0.00 | 454.14 | 1,017.84 | 1,032.48 | 843.80 | 620.44 | 415.46 |
Average Common Equity |
— | (202.00) | (201.76) | 318.63 | 881.52 | 744.10 | 518.89 | 315.51 |
Columns are period end dates